Literature DB >> 6121891

Optical studies on the specific interaction of dipyridamole with alpha 1-acid glycoprotein (orosomucoid).

S El-Gamel, U Wollert, W E Müller.   

Abstract

The interaction of dipyridamole with alpha 1-acid glycoprotein was investigated by circular dichroism and ultraviolet absorbance measurements as well as by equilibrium dialysis experiments. Dipyridamole is bound to the protein via one site of extremely high affinity and by at least one site of considerably lower affinity. Only the association of dipyridamole with the high affinity site produces typical extrinsic Cotton effects. As a result of experimental observations it is concluded that the high affinity site is located in a hydrophobic protein structure of the glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121891     DOI: 10.1111/j.2042-7158.1982.tb04212.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  The influence of N-acetylneuraminic acid on the properties of human orosomucoid.

Authors:  M L Friedman; J R Wermeling; H B Halsall
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

2.  Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents.

Authors:  M L Friedman; K T Schlueter; T L Kirley; H B Halsall
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

Review 3.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

4.  Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs.

Authors:  D L Goolkasian; R L Slaughter; D J Edwards; D Lalka
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.